AbbVie Inc’s arthritis drug Humira and Roche Holding AG’s cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were not supported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis. Other top treatments by spending that were called out included Pfizer Inc’s pain drug Lyrica, Gilead Sciences Inc’s HIV drug Truvada, Amgen Inc’s cancer drug …read more
Source:: Yahoo Finance
